Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 741 participants.
Also called NCT02273726
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 741 participants
- Registry
-
NCT02273726
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Puerto Rico
- Registry status
- Completed
Technical summary
Registry record NCT02273726. Randomized; no masking; primary purpose treatment. Start 2015-01-15 (actual); primary completion 2018-09-19 (actual). Results posted on 2021-10-29.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
- Condition
- CKD Anemia in Stable Dialysis Patients
- Intervention (Drug)
- Epoetin Alfa
- Intervention (Drug)
- Roxadustat
- Lead sponsor
- Kyntra Bio
- Collaborator
- Astellas Pharma Europe B.V.
- Collaborator
- AstraZeneca
Record details
- Record id
cardio:ct-nct02273726- Content hash
ea161e1b2c7f26a6a4f30a312911cc420cdcfe4e04ea3f29b35d85d434004d34